Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026)
Pharvaris (PHVS) posted Income from Continuing Operations of 45254539.73 for Q1 2026, up 10.45% on a QoQ basis from 50534633.91 in Q4 2025, and up 5.93% year-over-year from 42720270.06 in Q1 2025.
Pharvaris (PHVS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharvaris' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45254539.73 for Q1 2026.
- Quarterly Income from Continuing Operations rose 5.93% year-over-year to 45254539.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 190651929.03 (down 19.33% YoY) and the FY2025 annual result came in at 194015239.2, down 37.29% from the prior year.
- Income from Continuing Operations was 45254539.73 for Q1 2026 at Pharvaris, up from 50534633.91 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7617572.58 in Q2 2022 and bottomed at 51023221.04 in Q2 2025.
- A 5-year average of 33576464.78 and a median of 34496988.71 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 58.38% — and 2023, when it plunged 210.34%.
- Pharvaris' Income from Continuing Operations stood at 41450118.2 in 2022, then advanced by 10.71% to 37010902.94 in 2023, then climbed by 6.79% to 34496988.71 in 2024, then plunged by 46.49% to 50534633.91 in 2025, then climbed by 10.45% to 45254539.73 in 2026.
- Business Quant data shows PHVS's Income from Continuing Operations at 45254539.73 in Q1 2026, 50534633.91 in Q4 2025, and 43839534.36 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | -45.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.25 Mn |
| Dec 31, 2025 | -50.53 Mn |
| Sep 30, 2025 | -43.84 Mn |
| Jun 30, 2025 | -51.02 Mn |
| Mar 31, 2025 | -48.11 Mn |
| Dec 31, 2024 | -34.50 Mn |
| Sep 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -31.86 Mn |
| Mar 31, 2024 | -29.82 Mn |
| Dec 31, 2023 | -37.01 Mn |
| Sep 30, 2023 | -25.37 Mn |
| Jun 30, 2023 | -23.64 Mn |
| Mar 31, 2023 | -24.16 Mn |
| Dec 31, 2022 | -41.45 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -7.62 Mn |
| Mar 31, 2022 | -17.90 Mn |
| Dec 31, 2021 | 34,559.40 Bn |
| Sep 30, 2021 | -10.62 Mn |
| Jun 30, 2021 | -18.30 Mn |